deltatrials
Recruiting INTERVENTIONAL NCT04771130

A Study of BGB-11417 in Participants With Myeloid Malignancies

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Sponsor: BeiGene

Conditions Acute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm
Interventions Azacitidine BGB-11417 BGB-11417 BGB-11417 Posaconazole
Updated 30 times since 2021 Last updated: Apr 21, 2026 Started: May 24, 2021 Primary completion: Feb 8, 2028 Completion: Feb 8, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04771130, this observational or N/A phase trial focuses on Acute Myeloid Leukemia and Myelodysplastic Syndromes and remains actively recruiting participants. Sponsored by BeiGene, it has been updated 30 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2021 – ~Oct 2021 · 7 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – ~Apr 2026 · 46 days · monthly snapshotApr 16, 2026 – Apr 28, 2026 · 12 days · daily APIApr 28, 2026 – present · 58 days · daily API

Change History

30 versions recorded

  1. Apr 28, 2026 — Present [daily]

    Recruiting

  2. Apr 16, 2026 — Apr 28, 2026 [daily]

    Recruiting

    Phase: PHASE1/PHASE2 → None

  3. Mar 2026 — Apr 2026 [monthly]

    Recruiting PHASE1/PHASE2

  4. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE1/PHASE2

  5. Dec 2025 — Feb 2026 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 25 earlier versions

  1. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE1/PHASE2

  2. Oct 2025 — Nov 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

  6. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE1/PHASE2

  7. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  8. Mar 2025 — May 2025 [monthly]

    Recruiting PHASE1/PHASE2

  9. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE1/PHASE2

  10. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

  11. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

  12. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  13. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  14. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  15. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  16. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  17. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  18. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  19. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  20. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  21. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  22. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  23. Mar 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  24. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Mar 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Contact Information

Sponsor contact:
  • BeiGene
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auckland, New Zealand , Barcelona, Spain , Beijing, China , Bologna, Italy , Chengdu, China , Clayton, Australia , Concord, Australia , Duarte, United States , Edinburgh, United Kingdom , Fitzroy, Australia and 36 more locations